2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates


Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 29 janvier 2020
Doi : 10.1016/j.jaad.2019.09.035
accepted : 17 September 2019
Restaging [18F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance

Sonia Mahajan, MD a, Christopher A. Barker, MD b, Audrey Mauguen, PhD c, Bhuvanesh Singh, MD d, Neeta Pandit-Taskar, MD a,
a Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 
b Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 
c Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 
d Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 

Correspondence to: Neeta Pandit-Taskar, MD, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065.Memorial Sloan Kettering Cancer Center1275 York AveNew YorkNY10065

There are no specific recommendations for [18F] fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in assessing recurrent cutaneous squamous cell carcinoma (cSCC).


To evaluate FDG-PET/CT in recurrent cSCC.


FDG-PET/CT scans were retrospectively reviewed. Sites of abnormal uptake were noted and correlated with biopsy/histopathology studies, where available, and with follow-up imaging or clinical data in others. Comparison with available CT/magnetic resonance imaging was performed. The prognostic significance of PET/CT parameters was evaluated, and PET/CT-based change in management was recorded.


A total of 115 FDG-PET/CT scans were analyzed in 100 consecutive patients with cSCC. Of these, 96 (84%) scans were positive for recurrence, and 25 showed distant metastases. PET/CT detected unsuspected disease sites in 39 of 115 scans (34%), locoregional disease in 14, distant metastases in 11, both locoregional disease and distant metastases in 8, additional local cutaneous disease in 5, and second malignancy in 1. Comparison of 78 PET/CT scans with available CT/magnetic resonance imaging showed 37 additional abnormalities on 23 PET/CT scans, predominantly including skin/subcutaneous lesions and nodes. PET/CT led to change in management in 28% of patients. On univariate/multivariate analysis, increased number of FDG-positive lesions and lung metastases on PET/CT was associated with increased risk of death/disease progression.


Retrospective study.


FDG-PET/CT was sensitive in detecting recurrent disease in cSCC, led to change in management for 28% of patients, and proved to be of prognostic value.

The full text of this article is available in PDF format.

Key words : cutaneous, FDG-PET/CT, neoplasm, oncology, positron emission tomography, prognosis, recurrent, restaging, squamous cell carcinoma

Abbreviations used : cSCC, CI, CT, FDG, HR, MR, PET, SUV, TTP

 Funding sources: Supported in part through the National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748.
 Disclosure: Dr Pandit-Taskar has served as a consultant to Y-mAbs Therapeutics, Inc; has served on the advisory board of Progenics; has received honoraria from Progenics and MedImmune/AstraZeneca; and has conducted funded research studies with ImaginAb. Dr Barker reports grants from Amgen, Elekta, and Merck outside the submitted work. Drs Mahajan, Mauguen, and Singh have no conflicts of interest to declare.
 IRB approval status: Reviewed and approved by MSKCC's institutional review board.
 Reprints not available from the authors.

© 2019  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline